Potential surrogate endpoints in cancer research – some considerations and examples | Zendy

Duffy S. W. | Zendy; Treasure F. P. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Potential surrogate endpoints in cancer research – some considerations and examples

Author(s) -

Duffy S. W.,

Treasure F. P.

Publication year - 2011

Publication title -

pharmaceutical statistics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.421

H-Index - 38

eISSN - 1539-1612

pISSN - 1539-1604

DOI - 10.1002/pst.406

Subject(s) - surrogate endpoint , clinical endpoint , endpoint determination , clinical trial , medical physics , medicine , computer science

We present an introductory survey of the use of surrogates in cancer research, in particular in clinical trials. The concept of a surrogate endpoint is introduced and contrasted with that of a biomarker. It is emphasized that a surrogate endpoint is not universal for an indication but will depend on the mechanism of treatment. We discuss the measures of validity of a surrogate and give examples of both cancer surrogates and biomarkers on the path to surrogacy. Circumstances in which a surrogate endpoint may actually be preferred to the clinical endpoint are described. We provide pointers to the recent substantive literature on surrogates. Copyright © 2009 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research